Proellex-V

Proellex-V is a proprietary vaginal suppository formulation of telapristone acetate, a synthetic, steroidal selective progesterone receptor modulator (SPRM) that functions as an anti-progestin by antagonizing the progesterone receptor in progesterone-sensitive tissues. Developed by Repros Therapeutics as a local vaginal delivery alternative to oral Proellex, it was investigated primarily for the treatment of symptomatic uterine fibroids, with the goal of reducing excessive menstrual bleeding and fibroid-related symptoms while maintaining systemic estrogen levels and thereby preserving bone mineral density. By opposing progesterone’s proliferative and survival signals in uterine and fibroid tissue, Proellex-V is intended to shrink progesterone-sensitive tumors and improve quality-of-life measures such as bleeding scores and symptom severity, with vaginal delivery designed to optimize systemic exposure and mitigate liver toxicity observed with higher-dose oral telapristone.

Brand names

Proellex-V

Other names

telapristone acetate vaginal suppositorytelapristone vaginal formulationtelapristone suppository